Desloratadine Has No Clinically Relevant Electrocardiographic or Pharmacodynamic Interactions with Ketoconazole

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2165/00003088-200241001-00006PMID 12169045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Pharmacokinetic Profile of Desloratadine in Healthy Adults, Including Elderly

  2002cited by this paper
• Effect of Race and Sex on Single and Multiple Dose Pharmacokinetics of Desloratadine

  2002cited by this paper
• Lack of Clinically Relevant Interaction Between Desloratadine and Erythromycin

  2002cited by this paper
• Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis

  2001cited by this paper
• Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist2nd Communication: Lack of central nervous system and cardiovascular effects

  2000cited by this paper
• Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist

  2000cited by this paper
• Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity

  1999cited by this paper
• Arrhythmogenic mechanisms of non‐sedating antihistamines

  1999cited by this paper
• Cardiovascular profile of loratadine

  1999cited by this paper
• Blockade of HERG and Kv1.5 by ketoconazole.

  1998cited by this paper
• Blockade of HERG and Kv 1 . 5 by Ketoconazole 1

  1998cited by this paper
• Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.

  1998cited by this paper
• Combined use of astemizole and ketoconazole resulting in torsade de pointes.

  1997cited by this paper
• Treating Allergic Rhinitis with Second‐Generation Antihistamines

  1996cited by this paper
• Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity.

  1995cited by this paper
• Torsades de Pointes after treatment with terfenadine and ketoconazole.

  1992cited by this paper

• Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil

  2023cites this paper
• Structural and clinical impact of anti-allergy agents: An overview.

  2019cites this paper
• Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies.

  2019cites this paper
• Cardiac safety of second‐generation H1‐antihistamines when updosed in chronic spontaneous urticaria

  2019cites this paper
• Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

  2018cites this paper
• Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials

  2016cites this paper
• Second-generation antihistamines

  2016cites this paper
• Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial

  2016cites this paper
• SYSTEM-DEPENDENT METABOLISM OF DRUGS BY CYTOCHROME P450: THE MECHANISTIC BASIS FOR WHY HUMAN LIVER MICROSOMES ARE SUPERIOR TO HUMAN HEPATOCYTES AT METABOLIZING MIDAZOLAM BUT INFERIOR AT METABOLIZING DESLORATADINE

  2015cites this paper
• A long-standing mystery solved: The formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UGT2B10 is an obligatory requirement

  2015cites this paper
• A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement

  2015cites this paper
• The use of New Generation H1 Receptor Blockers and Advantages in Terms of Reliability

  2014cites this paper
• Does desloratadine alter the serum levels of montelukast when administered in a fixed‐dose combination?

  2013cites this paper
• Safety evaluation of desloratadine in allergic rhinitis

  2013influential citation
• Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males

  2012cites this paper
• Desloratadine

  2012cites this paper
• Treatment of Allergic Rhinitis in Infants and Children

  2012cites this paper
• Second-Generation Antihistamines

  2012cites this paper
• Antihistamines (H1 receptor antagonists)

  2010cites this paper
• Histamine, histamine receptors and antihistamines: new concepts.

  2010cites this paper
• Histamina, receptores de histamina e anti-histamínicos: novos conceitos

  2010cites this paper
• Drug interactions

  2009cites this paper
• New oral H1 antihistamines in children: facts and unmeet needs

  2008cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Desloratadine, Fexofenadine and Levocetirizine

  2008cites this paper
• New antihistamines: a critical view.

  2006cites this paper
• Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

  2006cites this paper
• Combining desloratadine and pseudoephedrine in the treatment of seasonal allergic rhinitis

  2006cites this paper
• Desloratadine for allergic rhinitis

  2006cites this paper
• Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety

  2006cites this paper
• Effect of H1 antihistamines upon the cardiovascular system.

  2006cites this paper
• Letter to the editorThe authors' reply

  2006cites this paper
• Cardiotoxicité des antihistaminiques de deuxième génération

  2006cites this paper
• Revue générale Cardiotoxicité des antihistaminiques de deuxième génération ☆ Cardiotoxicity of second generation antihistamines

  2006cites this paper
• Interactions of the H 1 antihistamines

  2006cites this paper
• The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug Interactions

  2005cites this paper
• The Safety and Efficacy of Desloratadine for the Management of Allergic Disease

  2005cites this paper
• Design and Data Analysis in Drug Interaction Studies

  2005cites this paper
• Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders

  2005cites this paper
• Antihistamines (H 1 receptor antagonists)

  2005cites this paper
• Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis.

  2005cites this paper
• Disposition of desloratadine in healthy volunteers

  2005cites this paper
• Safety of desloratadine syrup in children

  2004cites this paper
• Pharmacokinetics/Pharmacodynamics of Desloratadine and Fluoxetine in Healthy Volunteers

  2004cites this paper
• The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine

  2004influential citation
• Comparative Pharmacology of Guinea Pig Cardiac Myocyte and Cloned hERG (IKr) Channel

  2004cites this paper
• L'analyse des critères des antihistaminiques ARIA/EAACI : exemple d'un antihistaminique de dernière génération

  2004cites this paper
• Reported Case of Severe Hepatotoxicity Likely due to Fluconazole and Not Desloratadine

  2004cites this paper
• Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans

  2004cites this paper
• Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude.

  2004cites this paper
• Chronic idiopathic urticaria for the generalist.

  2003cites this paper
• Gateways to clinical trials. March 2003.

  2003cites this paper
• Desloratadine: A Nonsedating Antihistamine

  2003cites this paper
• Antihistamines.

  2003cites this paper
• Studies on performance and sleepiness with the H1-antihistamine, desloratadine.

  2003cites this paper
• Pharmacoepidemiology and drug safety.

  2003cites this paper
• A Pharmacokinetic Profile of Desloratadine in Healthy Adults, Including Elderly

  2002cites this paper
• Desloratadine: A new, nonsedating, oral antihistamine.

  2001cites this paper
• Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis

  2001cites this paper
• Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.

  2001cites this paper